gbola amusa md cfa head hc research
sale trade et
sale trade et
share mil
initi buy rix reward stori
initi coverag meiragtx buy rate
forward-look approach meira taken develop one
broadest pipelin aav-bas gt one large-
chardan focu coverag compani potenti
invest return creation real valu societi
believ aav-bas gene therapi gt player meiragtx one
compani prime signific long-term return ocular salivari
neurodegen diseas franchis contribut broader
arriv gt believ investor take notic speed
manag execut lead differ phase i/ii
readout meiragtx differ indic xlrp
achromatopsia
new differ program enter clinic
achromatopsia sjgren syndrom al wet
detail model clinic product forecast billion risk-
adjust sale meiragtx see figur drive
pt make high-convict pick aav-bas gt coverag
summar key driver buy rate
larg address market opportun billion phase
i/ii radiation-induc xerostomia rix remain
unmodel consensu note moderate-to-sever
us rix patient see figur one-tim price yield
billion market opportun diagnos radiation-tr
patient regularli engag medic profession
mani meira program fit predict proprietari
chardan gene therapi framework target monogen diseas
achm achm xlrp clear suitabl
phenotyp use tropic vector right deliveri
base meira explor profound lt upsid option asset
rix al wet alzheim diseas neurodeg
condit intrigu regulat gt platform
abund regulatori design see figur
robust kol network speed meira program exampl
see prime ftd tell signal speed
meira relationship exampl moorfield hospit
univers colleg london institut ophthalmolog preemin
retin diseas specialist enabl meira move faster
competitor exampl quickli recruit natur histori studi
sourc patient clinic trial
pleas refer import disclosur inform regul analyst certif found page report
meira manufactur de-risk rel peer meira lower demand capac due
focu ophthalmolog salivari gland indic alreadi built sq ft cgmp facil london
recent certifi investig medicin mhra gener enough materi support current
plan trial believ investor yet appreci meira manufactur capabl also
valid higher regulatori standard requir patient recruit europ
start phase i/ii trial achm
aav-rpgr report preliminari dose-escal data phase i/ii studi xlrp
report preliminari data patient pi/ii studi defici
report pi/ii data achm follow pivot trial start
report preliminari data phase i/ii trial rix collabor nidcr
file ind potenti start phase i/ii trial al
file ind potenti start phase i/ii trial wet
price target base probability-adjust model key franchis use dcf
wacc perpetu growth impli termin ebitda multipl deriv price target
npv/share radiation-induc xerostomia rix assum penetr
us market patient moderate-to-sever rix assum one-tim price
launch assum growth thereaft global estim appli risk
adjust forecast mm sale model peak risk-adjust sale mm
npv/share assum gene therapi cumul
penetr us achromatopsia market take share assum
one-tim price launch assum growth thereaft
global estim appli risk adjust forecast mm sale model
peak risk-adjust sale mm
aav-rpgr npv/share x-link retin pigmentosa xlrp assum cumul penetr
us x-link retin pigmentosa market aav-rpgr take share assum
aav-rpgr one-tim price launch assum growth thereaft
global estim appli risk adjust forecast mm sale model
peak risk-adjust sale mm
npv/share conserv model estim franchis
pipelin npv/share make vari assumpt meira pipelin candid
sjogren syndrom al wet
preclin discoveri phase candid
npv/share estim meira cash posit stood mm june
risk achiev target price
clinic risk gene therapi sector face import challeng safeti question exampl long-term
theoret risk cancer gene therapi rule immun toxic continu relev factor
trial recruit special issu orphan ultra-orphan diseas achromatopsia x-link retin pigmentosa
relat issu natur histori data rare diseas sometim definit enough
confirm paramet evolv untreat patient meira target slowli progress diseas
expos risk effect intervent may need long-term trial show efficaci indic like
xerostomia aav-bas gene therapi knowledg previous valid compani preclin
pipelin also target number novel target complex polygen diseas increas risk
regulatori aav-bas gene therapi product luxturna ever approv us regulatori
pathway prove complex and/or time consum anticip due unexpect chang leadership
fda could materially-neg impact project target price even result meira
xerostomia achromatopsia xlrp diseas franchis achiev target endpoint
page
product obtain regulatori approv risk-adjust project price target would expos downward
revis anoth concern approv may narrow indic expect may subject
commerci potenti meira target indic may larg project possibl due
competit note competit achromatopsia agtc buy xlrp nightstar
buy agtc buy neutral market gene
therapi indic luxturna gene therapi case potenti one-tim product durabl
benefit believ new price model pay-for-perform up-front price base expect
multi-year benefit need optim return valu gene therapi compani meet unmet medic need
gene therapi compani permit price potenti one-tim therapi line exist orphan drug
base recur use could downsid estim lastli meira burn cash
build sale market medic affair infrastructur us possibl global region
intellectu properti use achromatopsia program may lead royalti paid delay
launch assumpt
manufactur aav-bas gene therapi product novel complex rel difficult manufactur risk
meira see delay develop and/or commerci product note higher frequenc
manufactur setback difficult-to-mak product vaccin time therapeut space
financ risk meira may need rais addit capit perhap via equiti financ reach profit
potenti result share dilut sharehold
stock price volatil share price volatil common development compani biotechnolog sector
meiragtx hold plc london-bas clinical-stag biotechnolog compani focus develop
commerci pipelin novel potenti cur one-tim gene therapi target ocular salivari gland
neurodegen diseas meira util adeno-associ viru aav -base deliveri system
advantag low pathogen low predict integr host cell genom low immunogen
lead ophthalmolog product candid treatment
treatment aav-rpgr treatment x-link retin pigmentosa xlrp phase
i/ii studi addit meira run phase i/ii studi xerostomia collabor nation
institut dental craniofaci research nidcr nih compani pipelin preclin candid
treat ophthalmolog salivari gland indic well amyotroph later sclerosi meira strong
relationship moorfield hospit univers colleg london mani technolog
develop meiragtx establish
page
summari meira deep differenti pipelin vari risk-reward dynam
risk cgtf approach overal meira thesi
radiation-induc xerostomia rix model mm risk-adj sale npv/share
achromatopsia model mm risk-adj sale npv/share
aav-rpgr x-link retin pigmentosa xlrp model mm risk-adj sale npv/share
model mm risk-adj sale
wet model mm risk-adj sale npv/share
catalyst pipelin meira consider clinic poc dataflow
chardan gene therapi framework meira clinic pipelin gener fit predict framework
year-to-d vivo gene therapi market movement august vs decemb
aav-bas gene therapi comp top pick uniqur also chardan top pick
small rna therapi comp alnylam top pick srna gene therapi offer favor risk-reward dynam
vivo gene edit see greater upsid potenti intellia buy toolgen buy
background treatment xerostomia
radiation-induc xerostomia number manifest impair qol
xerostomia might address gene therapi increas express aquaporin
meira current test phase i/ii trial xerostomia
background treatment achromatopsia achm
achromatopsia rare inherit condit caus loss color vision
meira address mutat aav-bas gt
preclin result suggest effect mous model
phase i/ii studi on-going data due
preclin result suggest therapi also effect mous model
natur histori achromatopsia demonstr stabl diseas time
achromatopsia competit landscap domin meira agtc
background aav-rpgr treatment x-link retin pigmentosa xlrp
x-link retin pigmentosa progress ird affect male
meira use variant rpgr gene delet
page
meira construct restor rpgr express rod function mous model
aav-rpgr also support glutamyl newly-appreci modul rpgr function
natur histori xlrp well-studi prospect trial on-going plan
meira measur size ellipsoid zone surrog degener
meira on-going phase i/ii trial aav-rpgr adult patient
xlrp competit indic given multipl on-going aav-bas gt trial
background treatment diseas
encod enzym critic vision mutat lead multipl type ird
meira gener product improv ucl precursor
meira also conduct natur histori studi understand diseas progress
luxturna approv improv mlmt without va chang
meira phase i/ii trial ol studi use fellow eye control
meira construct luxturna target patient
background preclin program develop
aav-aipl releas compassion use uk
preclin studi underway develop therapi dri wet
meira develop aav-bas therapi treat multipl form al
meira also develop aav-bas therapi treat alzheim diseas
novel mammalian riboswitch may allow meira develop tunabl
background meira remark in-hous manufactur capabl
sale key product
page
summari meira deep differenti pipelin vari risk-reward dynam
initi coverag meiragtx buy pt see meira dynam player ophthalmolog gene therapi gt
non-ophthalmolog salivari gland neurodegener pipelin drive profound upsid scenario
meira clinical-stag asset focus eye salivari gland neurodegen diseas agreement
predict chardan gene therapi framework meira address multipl monogen inherit retin diseas
ird proof compani abil develop safe effect phase i/ii trial ird alreadi underway
name leber congenit
amaurosi lca aav-rpgr x-link retin pigmentosa xlrp
trial expect start data on-going trial
expect see figur figur figur patient suffer ird suffer
achromatopsia xlrp significantli impair vision either birth achromatopsia
progress worsen throughout life xlrp few-to-no treatment option
indic repres one rel high unmet medic need competit indic gt agtc
buy conduct trial form achromatopsia xlrp spark
therapeut neutral approv market gt luxturna treatment nightstar
therapeut buy on-going clinic trial xlrp believ meira well-posit success
due abund evid progress meira product clinic quickli gener
key regulatori design see figur also data like cost effici competitor meira robust
relationship moorfield hospit ucl institut ophthalmolog unit kingdom
greatli facilit patient identif recruit evidenc on-going natur histori nh studi
accompani sourc patient meira phase i/ii trial potenti pivot trial meira manufactur
capabl valid higher regulatori standard requir patient recruit europ
beyond ird meira address polygen diseas and/or much larger market often target uniqu pathway
meira clinical-stag asset gt design drive express import water
transport salivari gland restor saliva product patient radiation-induc xerostomia rix xerostomia
extrem form dri mouth caus saliva-produc acinar cell die radiat use treat head neck
oral cancer also caus autoimmun destruct salivari gland condit sjogren
syndrom xerostomia character reduct volum saliva concurr chang salivari
consist ph alter lead pain difficulti eat swallow tast speak
patient report overal reduct qualiti life qol impair normal social activ xerostomia
perman meira test abil drive saliva product ductal cell salivari gland
radiation-resist express aquaporin produc saliva normal condit
knowledg gt compani target xerostomia give meira uniqu advantag estim
patient us alon could benefit therapi although rix genet diseas risk-
adjust confid see figur meira abil execut indic due exist proof-of-concept data use
adenoviru vector-bas gt see studi radiation-induc xerostomia on-going collabor
nation institut dental craniofaci research nidcr data expect addit
baum bj et al earli respons adenoviral-medi transfer cdna radiation-induc salivari hypofunct
page
trial slate begin note meira also work preclin product age-rel
macular degener true mass-market opportun well neurodegen condit like amyotroph
later sclerosi al potenti alzheim diseas parkinson diseas target indic
differ gt program exampl target rna regul via nonsense-medi decay al
differenti meira model modest sale al wet program see figur
still pre-clin success one would provid tremend upsid compani
market miss radiation-induc xerostomia rix though riski extrem larg market opportun
form xerostomia primarili affect patient cure head-and-neck cancer patient
alreadi healthcar system treat signific intervent radiat cancer
erad xerostomia becom popul primari concern life-threaten rix caus sever
impair qualiti life drive potenti costli sequela includ dental cari tooth decay increas
risk oral infect rix patient repres remark opportun meira well-monitor physician
visit doctor and/or dentist least per year follow-up dearth effect option manag
xerostomia understand patient physician motiv util someth novel like gene therapi per
figur rix market grow rapidli base seer estim moderate-to-sever patient
could launch one-tim price equival rough
estim cost tooth replac patient procedur sometim done multipl time gener
bn sale opportun unit state model risk-adjust peak sale mm
meira remark clinic trial momentum move program expediti clinic end
compani may program clinic al rix sjogren syndrom
wet and/or xlrp regulatori design see figur gener far includ prime design
confirm set credibl program credibl platform us breadth pipelin
accompani diversifi strategi target differ organ differ indic togeth modest valuat
mm market cap markedli increas probabl out-performance
stock price appreci target often seek long-term emphas meira transit effici
preclin stage clinic trial number indic year move ahead earlier-
establish competitor us abil execut quickli may give meira edg space
numer regulatori design us support meira acceler trajectori figur meira clinic
stage asset receiv rang design fda ema prime track design ftd
ftd aav-rpgr provid increas regulatori interact potenti acceler approv
clear benefit competit landscap note prime design associ numer
breakthrough product see figur addit pediatr diseas design rpdd aav-
may also provid upsid sale prioriti review voucher prv obtain upon approv mani
design requir support evid efficaci emphas high qualiti meira preclin
packag confid agenc regard compani abil execut clinic increas visibl
regul well benefit embed design make extens list major posit meira
page
figur meira obtain extens regulatori design clinical-stag asset see associ alpha gener
could prove dynam year meira given potenti clinic program see figur figur figur
start phase i/ii trial achromatopsia
aav-rpgr report preliminari dose-escal data phase i/ii studi xlrp
report preliminari data patient phase i/ii studi
report phase i/ii data achromatopsia follow pivot trial start end
report preliminari data phase i/ii trial rix collabor nidcr
file ind potenti start phase i/ii trial al
file ind potenti start phase i/ii trial wet
clinic asset larg fit predict chardan gene therapi framework cgtf address unmet medic need
framework figur gener proven predict call potenti potenti aav-bas
origin diseas exemplar breakthrough therapi design and/or prime design
chardan uniqu predict mydicar heart failur wet failur
page
ema odd ema ftd fda rpdd fda odd ema odd fda odd ema odd fda odd ema odd fda ftd provid frequent engag fda meet written commun acceler approv prioriti review qualifi well roll reivew bla competit indic ftd could competit advantag odd fda ema provid market exclus financi incent includ reduc fee tax credit fda comment odd fda provid market exclus financi incent includ reduc fee tax credit odd fda provid market exclus financi incent includ reduc fee tax credit prime allow guidanc overal develop plan scientif advic prescrib mileston increas commun regul acceler assess market applic see prime design sourc alpha ftd provid frequent engag fda meet written commun acceler approv prioriti review qualifi well roll reivew bla competit indic ftd could competit advantag rpdd may provid prioriti review voucher use obtain prioriti review futur product sold anoth develop sale prioriti review voucher prv obtain compani rpdd could sourc addit upsid rpdd may provid prioriti review voucher use obtain prioriti review futur product sold anoth develop sale prioriti review voucher prv obtain compani rpdd could sourc addit upsid odd fda ema provid market exclus financi incent meiragtx hold plc
gene therapi space see potenti meira clinical-stag asset base target monogen diseas
gener proof-of-concept clinic data achromatopsia xlrp clear phenotyp
photophobia lack color vision progress vision loss use right deliveri vector tropic target
tissu deliv retina unclear much protein requir rescu vision
diseas given small target tissu volum possibl aggreg protein level requir
meaning biolog effect low end note xerostomia genet diseas make riskier indic
estim howev publish clinic data trial us support model chanc
success mani ird patient suffer achromatopsia xlrp limit option address
either symptom diseas underli caus approv luxturna provid therapi
defici patient may limit meira market thu conserv model sale re-
assess view data rix prescript medic pilocarpin cevimelin
prescrib improv salivari flow come side effect includ excess sweat gastrointestin
distress must taken sever time day see clear opportun one-tim treatment indic
anim data show efficaci meira ophthalmolog use either anim relev gene
knock cell cultur system deriv ird patient cell meira demonstr appropri protein express
local within retina addit evid multipl model function improv
treatment includ restor erg wave appropri post-transl modif protein like rpgr
anim model reliabl human studi result far broadli give us confid meira pipelin
meira work top institut ophthalmolog beyond enabl value-enhanc access patient
origin found spin-out univers colleg london ucl meira relationship doctor moorfield
hospit one world premier ophthalmolog center moorfield one extens
patient databas ird connect enabl meira move quickli clinic allow meira move past
agtc certain indic note meira relationship provid access patient treatment also
longitudin natur histori studi see import compon interpret result gt program
feed regulatori file beyond ophthalmolog meira work nidcr conduct
previou clinic trial aquaporin gt therefor see anoth import strateg collabor
ophthalmolog gt regulatori price distribut preced establish luxturna
approv luxturna model success late-stag trial design execut meira phase i/ii studi
success see rel clear path regulatori approv pivot trial phase
meira strong in-hous manufactur written often import intern
manufactur capabilities/capac see arbit long-term success gt space meira construct
cgmp manufactur facil london recent certifi mhra dose patient
europ us strong signal european regul known stricter manufactur standard
investig product prior use human fda inspect manufactur facil product
carvalho ls et al long-term age-depend restor visual function mous model achromatopsia
georgiadi et al develop optim gene therapi vector leber congenit amaurosi owe defect
pawlyk bs et al photoreceptor rescu abbrevi human rpgr gene murin model x-link retin pigmentosa gene
page
bla submiss phase addit understand stringent qualiti control requir place
eu suggest deep institut knowledg meira produc highest qualiti note
european investig product must conform eudralex volum detail gmp requir
includ manufactur steril medicin product investig medicin product batch releas protocol
eu regul also call qualifi person qp respons final releas product whose
name must includ facil licens fda guidelin gmp us regul
formal requir earli investig product understand rare inspect facil even phase ii
materi hail compani like novarti nr oxford biomedica unrat manufactur team meira
assembl consider experi gt manufactur qc regulatori interact addit de-risk
compani rel peer ophthalmolog gt requir far less vector rel target organ lessen
burden earli product provid greater flexibl use meira capac exampl gensight
biolog buy requir vg per eye phase i/ii studi nightstar buy util
vg phase studi meira line slightli comp use rang vg
vg trial still order magnitud less vector appli
system elsewher non-ophthalmolog gene therapi indic
page
risk cgtf approach overal meira thesi
meira target certain competit indic see ophthalmolog among least riski space gt due
approv preced treatment immunoprivileg site low vector dose use note meira face
competit everi ophthalmolog indic compani current pursu exampl agtc clinic stage
program achromatopsia anticip complet dose-escal phase trial
respect around time meira nightstar one high convict name space
present safeti efficaci data phase i/ii xlrp trial septemb includ patient data dose
cohort least month post-treat follow-up patient agtc also guid complet dose-
escal xlrp trial final luxturna launch dose patient limit market
meira alreadi limit market opportun although al wet large-market indic leav
room multipl winner note gt competit follow al unrat avexi
novarti compani nr among other although acknowledg meira approach could potenti appli
broader rang patient wet buy chardan top pick
neutral agtc buy xerostomia differenti indic gt space carri greater risk
genet condit previou gt approach shown modest success mean optim need
administr via subretin inject particularli fovea certain describ risk
previou research ophthalmolog gt includ cataract retin tear retin detach among
other innov around sri gene therapi develop intra-op
optic coher tomographi risk remain meira choos administ foveal region
highest concentr cone damag occur region howev patient may lose residu vision
prior treatment note histor complic greatli address also led
advers treatment outcom patient case receiv benefit due sub-optimal dose retin
meira reportedli execut foveal procedur safe patient treat far possibl exist
complic aris larger trial potenti advers tilt risk-reward dynam
amount protein express requir benefit certain target indic known favor use
gt diseas small amount protein strong biolog result meira clinic stage asset unknown
much protein express requir see benefit see figur even ophthalmolog enter late-
stage develop clear us field good metric assay understand paramet
eye small organ possibl mani live cell remain diseas must express high level protein
order improv vision outcom known trial read even difficult
assess express possibl take biopsi thu remain long-term risk meira approach eye
may true salivari gland xerostomia given target cell produc saliva
baselin program may requir larg amount aquaporin express restor salivari flow
xue et al techniqu retin gene therapi deliveri viral vector subretin space lond
edward tl et al visual acuiti retin gene therapi choroideremia engl
page
radiation-induc xerostomia rix model mm risk-adj sale npv/share
figur radiation-induc xerostomia rix model launch risk-adjust peak sale mm initi yearli us price
page
million unit state sale million sale yoy statespopul cancer incid per cancer death per caviti pharynx cancer patient previous incid new caviti pharynx cancer diagnosi radiotherapi patient develop xerostomia patient moderate-to-sever moderate-to-sever treat gene therapi new patient treat one-tim price sale yoy plc
achromatopsia model mm risk-adj sale npv/share
figur achromatopsia model launch risk-adjust peak sale mm initi yearli us realiz price
page
million unit state sale million sale yoy agtc unit state sale achm agtc million sale achm agtc yoy statespopul treat gene therapi patient treat gene share share achm share patient patient achm patient price achm gene sale gene therapi yoy sale sale achm agtc product meiragtx hold plc
aav-rpgr x-link retin pigmentosa xlrp model mm risk-adj sale npv/share
figur aav-rpgr x-link retin pigmentosa xlrp model launch risk-adjust peak sale mm initi yearli us realiz price
page
million nite unit state sale nsr-rpgr nite million sale nsr-rpgr nite yoy unit state sale aav-rpgr million sale aav-rpgr yoy statespopul treat gene therapi patient treat gene share nsr-rpgr share aav-rpgr share share product patient nsr-rpgr patient aav-rpgr patient patient product price xlrp advanc sale xlrp gene therapi yoy sale nsr-rpgr nite sale aav-rpgr sale agtc product plc
model mm risk-adj sale
wet model mm risk-adj sale npv/share
figur wet amdw model mm risk-adjust us sale initi us price
page
million sale vector gene therapi adverum target agtc etc risk-adjust gene therapi sale wet yoy statespopul advanc incl ga treat anti-vegf anti-vegf biolog anti-vegf gene therapi gt share anti-vegf non-gt biolog avastin biosimilar patient anti-vegf biolog share share share avastin biosimilar patient anti-vegf gene therapi patient anti-vegf gene therapi share share share agtc gt share gt share gt patient patient patient agtc gt agtc patient patient gt etc one-tim treatment gt sale anti-vegf gene therapi yoy adverum target agtc etc meiragtx hold plc
catalyst pipelin meira consider clinic poc dataflow
figur catalystsmeira plan soon report result aav-rpgr
page
dateeventchardan gt updat pi/ii trial design euretina could speed past agtc come competit prelim nightstar pi/ii xiriu studi data xlrp euretinaw expect trial posit readacross retin gt complet adult dose pi/ii xlrpmax adult pt dose cohort endpt measur mo gt pcd pi/ii trial endpoint safeti endpoint includ retin structur competit pcd agtc pi/ii trial toxic concern earli patient gt dose pi/ii expans cohort xlrpin pediatr extens cohort patient treat therapeut competit begin expans studi nightstar pi/ii xiriu trial pt therapeut dose pt control low gt isg initi trial gr rix phase i/ii trial alreadi on-going nih dental gt complet pi/ii trial adult pediatr pt endpt measur mo gt initi capsid studi non-human primatespreclin rodent studi use constitut cba gt complet toxicolog studi gmp manufactur competit start nightstar xolari nh studyth compani guid complet studi across multipl gt pcd pi/ii trial endpoint safeti endpoint includ retin structur competit pcd nightstar ol dose-escal pi/ii xiriu outcom safeti outcom chang bcva competit complet dose-escal agtc pi/ii trial compon differ meira competit complet dose-escal agtc pi/ii trial xlrpagtc use differ capsid partial codon-optim competit pcd agtc phase i/ii dose-escal trial use differ capsid promot gt initi pi/ii trial materi releas trial mirror gt complet ped dose pi/ii xlrpup pediatr patient treat dose gt prelim d-e data pi/ii trial xlrpwe believ xlrp could one import earli success gt initi manufactur cgmp product clinic trial compani plan pre-ind meet around time gt report pi/ii data includ adult dose-escal result mo pediatr gt prelim data pi/ii pt def readout includ safeti improv retin structur competit data expans cohort nightstar pi/ii xiriu pt therapeut dose pt control low competit pcd nightstar nh studi outcom va vi etdr measur gt isg interim phase i/ii data rix nih believ investor underappreci vast rix competit data nightstar ol dose-escal pi/ii xiriu pt first-in-human attempt x-link retin gt initi pivot trial meet regul defin path registr preced trial gt isg initi pi/ii trial sjogren syndromesjogren autoimmun destruct salivari gland caus competit complet dose escal agtc pi/ii trial far trial enrol patient relativli slowli pt total gt file ind initi pi/ii trial may provid strategi treat broad rang al gt file ind initi pi/ii trial wet amdconstruct would constitut develop regul express plc
figur catalystsmeira could start least one pivot trial
page
gt pcd pi/ii studi endpoint safeti endpoint includ retin structur competit data nightstar expans cohort pi/ii xiriu pt therapeut dose pt control low gt pcd nh studi pt observ year measur retin structur function plu competit pcd agtc nh clinic evalu studi mutat character diseas test variabl competit pcd agtc aav-rpgr dose-esc pi/ii trial xlrpsimilar aav-rpgr vector rout administr partial codon gt isg pcd pi/ii trial gr rix endpoint safeti endpoint chang salivari flow gt pcd nh studi pt observ year measur retin structur gt pcd pi/ii long-term fu lcaall patient pediatr adult roll-ov add year gt pcd pi/ii long-term fu patient pediatr adult roll-ov add year expiri patent uclb brandei includ patent famili rpgr dri expect expiri company-own patentsthes includ method use composit matter achromatopsia achromatopsia al amyotroph later sclerosi age-rel macular degener bcva best correct visual acuiti d-e dose-escal lca leber congenit amaurosi nh natur histori ol open label pcd primari complet date endpoint rix radiation-induc xerostomia subretin inject visual function xlrp x-link retin pigmentosa plc
figur meira pipelin focus initi diseas eye salivari gland central nervou system
page
product candidatenear-term milestonesww ab cdna gt eye drop wet age-rel macular degener wet file ind start p/ii aav up-frameshift cdna gt amyotroph later sclerosi al initi head-to-head capsid studi nhp initi cgmp product manufactur file ind initi pi/ii studi cdna gt salivari gland inject radiation-induc xerostomia rix initi trial gr rix collabor mskcc interim phase i/ii cdna gt salivari gland inject sjogren syndrome-induc xerostomia initi pi/ii codon-optim proprietari promot cdna gt defici report preliminari data patient pi/ii studymeiragtxaav-rpgr stabil rpgr-orf hrk promot cdna gt x-link retin pigmentosa xlrp complet pi/ii adult cohort dose pi/ii pediatr expans cohort complet pi/ii ped cdna hcar promot gt achromatopsia pi/ii trial design updat euretina vienna complet pi/ii dose pi/ii studi readout initi pivot codon-optim promot gt achromatopsia complet tox studi initi pi/ii studymeiragtxstag developmentpreclinphas plc
chardan gene therapi framework meira clinic pipelin gener fit predict framework
corpor report chardan note disclosur current rate
figur predict chardan gene therapi framework suggest meira clinic pipelin like posit success particularli ophthalmolog candid
page
organizationdata releasedd datamonogen diseas chosen clear suitablephenotyp express effect tropic vector promot suitabl deliveri phase i/ii data spinal muscular atrophi type sma btd cnsivspark phase data inherit retin diseas btd due retinasubretin injectionbluebird biolentiglobin phase data sickl cell beta thalassemia major btd bs/bsye sever scd -thalassemia majoryes/no hbay lentiviru stem cellsex vivo st jude ucl durabl effect seen human liver hemophilia btd prime subject activ roughli normal btd deriv liverivfailuresavalanch phase iia data wet age-rel macular degener retinasubretin injectioncelladon corporationmydicar phase ii data advanc heart ii iv cardiacintra-coronari phase ii data parkinson cnsbi-later ic one-tim injectionsmeiragtx preclin data achromatopsia retinasubretin preclin data due retinasubretin injectionmeiragtxaav-rpgr preclin data xlrp due rpgrcould retinasubretin phase data vector patient grade radiation-induc xerostomiacould salivari glandsalivari gland injectiondiseas geneticsdeliveri meiragtx hold plc
year-to-d vivo gene therapi market movement august vs decemb
corpor report factset chardan note mention stock unrat unless otherwis state
figur select ytd price movement august vivo gt perform aav srna ivg
page
indic basketstickerratingccm ptupsideclosechang changemc mm genet medicin cap genet medicin vivo cap genet medicin ex vivo cap gene therapytickerratingccm ptupsideclosechang changemc mm solid genet rna therapytickerratingccm ptupsideclosechang changemc mm arrowhead edit non-matur tickerratingccm ptupsideclosechang changemc mm crispr meiragtx hold plc
aav-bas gene therapi comp top pick uniqur also chardan top pick
corpor report factset chardan note mention stock unrat unless otherwis state target market cap uncov name model current market cap
refer partner product avexi novarti compani wet hofh mp mp ii phase i/ii trial
figur select public aav-bas gene therapi companiesw prefer buy nite buy buy buy qure buy greater potenti drive upsid aav gt space
page
targettargetccmphas ofpric ccmccmdiluteddil mcpercentccm ptshare mmof sector mmof sectorhighhighp shareshareof genet technolog privat aav-bas genetherapi molecular askbio estev horama myonexu tamid meiragtx hold plc
small rna therapi comp alnylam top pick srna gene therapi offer favor risk-reward dynam
corpor report factset chardan note mention stock unrat unless state target market cap uncov name rgl silenc model current market cap
figur select public small rna therapi companiesw prefer buy greater potenti drive upsid entir small rna space
page
targettargetccmphas ofpric ccmccmdil mcpercentccm pt mmof sector mmof sectorhighshareof profitalnylam privat small rna therapi companiesadvirna silense sirnaom somagen sylentisnot benitec biopharma marina biotech addit unrat public compani plc
vivo gene edit see greater upsid potenti intellia buy toolgen buy
corpor report factset chardan note mention stock unrat unless otherwis state target market cap uncov name model current market cap
figur vivo gene editingw broadli expect out-performance crispr sector higher potenti perform buy toolgen buy
page
targettargetccmphas ofpric ccmccmdil mcpercentccm pt mmof sector mmof sectorhighshareof profitcrispr privat vivogen edit companiesbeam carib scienc egenesi excis exon feldan poseida precis scienc recombinet meiragtx hold plc
background treatment xerostomia
radiation-induc xerostomia number manifest impair qol
adapt maruyama eo et al plo one kielbassa et al lancet oncol chardan
figur xerostomia caus loss saliva-produc acinar cell vari sequela thereaft
saliva produc acinar cell number gland oral caviti
acinar cell arrang cluster feed intercal duct ultim flow excretori duct
saliva particularli import chewing/swallow tast protect oral tissu injuri
antimicrobi compound also carri saliva help distribut product oral caviti
radiat part head neck oral cancer treatment kill acinar cell collater lead xerostomia
xerostomia sever form dri mouth character chang volum consist ph saliva
induc earli cours radiotherapi rel low dose radiat
radiation-induc xerostomia symptom persist long radiat therapi end potenti
remaind patient life therebi greatli impair qualiti life qol
survey patient treat head neck cancer dirix et al cancer
complain dri mouth almost report pain report loss tast
radiation-induc xerostomia rix larg orphan indic potenti larg gene therapi market
per figur estim preval us oral caviti pharynx cancer patient
assum diagnosi radiotherapi rate develop xerostomia symptom
moderate-to-sever xerostomia estim patient moderate-to-sever xerostomia
page
xerostomia might address gene therapi increas express aquaporin
adapt delport oa biochem baum bj et al proc natl chardan
figur aquaporin critic water flow acinar cell
aquaporin famili protein channel regul passag water cell
differ aquaporin aqp exhibit tissue-specif express includ red blood cell
kidney salivari gland among other
flow passiv aqp osmot gradient establish ion transport
salivari gland acinar cell activ transport salt nacl water aquaporin creat primari
isoton fluid modifi nacl exchang potassium ion bicarbon
ductal cell produc final saliva solut
previou clinic studi indic express aqp non-acinar cell provid benefit xerostomia patient
acinar cell salivari gland sensit radiat cell like ductal cell
studi attempt drive aqp express particularli surviv cell restor saliva product
studi use adenovir deliveri note natur domin aquaporin
salivari gland evid increas salivari flow although highli variabl patient
page
meira current test phase i/ii trial xerostomia
adapt meiragtx clinicaltri gov chardan
figur meira collabor nidcr complet dose-escal trial
phase i/ii studi radiation-induc xerostomia rix current on-going
patient treat nation institut dental craniofaci research nidcr
dose-escal studi target patient grade radiation-induc xerostomia treatment head
neck cancer oral caviti free cancer year
deliv via vector transgen driven constitut cmv promot inject
directli parotid gland patient
baselin measur saliva gland architectur etc collect dose patient
follow-up exam year measur salivari output qol efficaci measur biopsi gland
endpoint safeti endpoint efficaci includ salivari output
data phase i/ii studi nidcr expect
clinic trial collabor memori sloan ketter cancer center slate begin
orphan drug design fda
meira plan test sjogren syndrom autoimmune-medi salivari gland destruct
page
adult per groupcohort vg/gland cohort assess month follow month follow month cohort vg/gland follow month cohort vg/gland follow month cohort vg/gland follow month plc
background treatment achromatopsia achm
achromatopsia rare inherit condit caus loss color vision
adapt prescott genom univers new hampshir thiaden aahj et al ophthalmolog chardan
figur achromatopsia extrem form color blind commonli caus mutat either
achromatopsia lead loss color vision due dysfunct cone photoreceptor
number gene contribut achromatopsia includ
meira use gt address achromatopsia driven case encod alpha
beta subunit cone photoreceptor cyclic nucleotide-g cng channel
importantli loss either subunit caus loss
achromatopsia affect individu inherit autosom recess pattern
rel type color blind achromatopsia much rarer far sever
achromatopsia symptom beyond loss color vision includ
hyperopia myopia less common
unlik rare inherit retin diseas achromatopsia progress diseas
problem often present earli infanc photophobia vision degener time
current effect treatment achromatopsia
tool address specif symptom diseas includ glass darken red lens filter
major white light standard prescript glass improv visual acuiti refract condit
page
meira address mutat aav-bas gt
adapt michalaki et al mol chardan
figur subunit subunit make cone channel left red box aav tropic photoreceptor requir right
meira develop aav-bas gene therapi gt address mutat
mutat compani use vector deliv transgen express control
human cone arrestin promot hcarp
mutat compani use vector deliv codon-optim transgen express
driven newly-develop synthet pan-con promot
key differ two therapi strength transgen express
order restor optim function proper stoichiometri subunit must preserv
hcarp promot much less activ promot preclin studi
therapi deliv via subretin inject order reach cone
although cone-trop aav readili cross inner limit membran eye requir
administr directli photoreceptor subretin space
unlik compani meira plan administ therapi close macula central region
retina highest concentr cone
page
preclin result suggest effect mous model
adapt carvalho ls et al mol genet chardan
figur mice treatment restor cone-medi respons
knock mous restor multipl aspect cone function
dose either vg/ey vg/ey abl restor cone-medi
electroretinogram erg measur demonstr anim normal scotop respons
measur rod function howev untreat anim lack cone-medi photop respons
respons restor aav treatment figur
photop respons closest wild type mice treat post-nat day figur
use optomotor measur aav treatment also shown improv visual acuiti treatment given
post-nat day post-nat day figur
contrast sensit impair anim alter treatment shown
effect therapi long-term leav hope potenti durabl respons human therapeut
one consider aris result howev appropri age treatment although
benefici respons efficaci diminish adult timepoint suggest earli intervent import
diseas mostli stabl birth cone death throughout life imped total rescu
would support idea pediatr treatment would provid greatest benefit
page
phase i/ii studi on-going data due
adapt clinicaltri gov corpor report chardan
figur meira phase i/ii trial includ adult dose cohort pediatr cohort
phase i/ii trial initi
importantli natur histori studi achromatopsia serv sourc patient run-in
us previous clinic hold compani address question
meira submit respons may may fda releas clinic hold
trial endpoint trial safeti addit endpoint includ improv visual function
improv retin function improv qualiti life qol
receiv number import regulatori design particularli prime ema
also receiv track design ftd fda pediatr diseas design
rpdd fda orphan drug design odd fda ema
meira anticip complet adult dose-escal cohort pediatr patient
meira may updat trial design septemb euretina top-line data present
discuss pivot trial design path regulatori approv anticip
compani aim initi pivot trial end
agtc also run phase i/ii trial progress delay see figur
page
enrol run-in nh adult per grouppediatr vg/ml cohort vg/ml follow assess month follow month follow month long-term follow year long-term follow year long-term follow year optim dose plc
preclin result suggest therapi also effect mous model
adapt meiragtx chardan
figur retina mous studi suggest restor cone function
shown restor express cone human mini retina
techniqu develop ucl gonzalez-cordero et al gene ther epub ahead print deriv
express robust figur
express seen subset cone cone blue cone red cone green figur
success target cone subset ideal restor wider rang vision patient
treatment knock mous also show function benefit
use erg measur studi see figur treatment restor electr
respons bright light compar wild type mous figur
respons dose-depend greater electr respons cone treat higher dose aav-
week treatment figur
dose test experi compar propos use clinic trial product
long-term tox studi cgmp-grade on-going initi
compani plan conduct studi month mice rat understand biodistribut toxicolog
toxicolog studi expect complet end
phase i/ii clinic trial slate begin adult pediatr patient
trial expect use design trial see figur
cgmp materi current product
lot expect releas trial begin
receiv posit opinion odd ema receiv odd fda
page
natur histori achromatopsia demonstr stabl diseas time
adapt langlo cs et al iov chardan
figur densiti outer nuclear layer onl thick correl retin grade
cross-sect studi smaller patient popul suggest loss cone time
diseas longitudin studi indic limit degener
longitudin studi patient aboshiha et al iov best-correct visual
acuiti bcva contrast sensit microperimetri stabl mean follow-up
fundu autofluoresc metric retin pigment epitheli cell health often use monitor
diseas progress highli variabl among patient
distinct pattern autofluoresc detect correl genotyp age
patient test longitudin show chang outer retina use spectral-
domain oct chang inner segment ellipsoid zone caus chang
bcva contrast sensit microperimetri suggest overal stabil retina
studi langlo cs et al iov demonstr also larg amount
variabl residu foveal cone structur patient mutat
studi peak cone densiti outer nuclear layer onl thick associ retin
grade figur age shown
overal oct grade howev significantli associ age shown
page
achromatopsia competit landscap domin meira agtc
adapt corpor present clinicaltri gov chardan
figur note meira agtc clinic program form achromatopsia use differ construct
page
namephaseprimari complet datetri dose-escal old adult treat first pediatr cone arrestin promot sequenc human gene pan-con promot use endogen gene provid appropri level express trial roll-ov year follow-up studi provid total year informationappli genet technolog old adult treat first pediatr l-opsin sequenc human gene select promot consid stronger specif hcar promot clinic trial dose reduc due tox concern codon optim may provid addit benefit need determin i/ii anticip design ol dose-escal old adult treat first pediatr pan-con sequenc human gene novel promot express strongli hcarp attempt address stoichiometri subunit requir codon optim may provid addit benefit need determin empiricallyappli genet technolog old adult treat first pediatr l-opsin sequenc human gene vector promot use construct result tox trial dose construct also reducedunivers hospit cone arrestin promot sequenc human gene vector promot meira trial diseas plc
background aav-rpgr treatment x-link retin pigmentosa xlrp
x-link retin pigmentosa progress ird affect male
adapt lyraki et al biochem soc transact megaw rd et al research chardan
figur rpgr import connect cilium retina rpgr contain region hotspot mutat
x-link retin pigmentosa xlrp ird caus progress loss vision ultim blind
x-link variant subset rp case
xlrp caus mutat rpgr x-link case gene
meira other develop therapi treat rpgr-mediat case xlrp
rpgr well-understood protein known critic structur cilia microscop
project surfac photoreceptor requir sens light figur
rp affect peopl xlrp account case patient us europ
studi suggest xlrp caus rapid degener variant rp
xlrp progress diseas caus death rod cone manifest vision loss
initi symptom night blind due rod death typic present decad life
follow loss central vision caus cone death typic patient complet
legal blind age
time approv therapi xlrp
patient often use low-vis aid chang progress diseas becom less effect
page
meira use variant rpgr gene delet
adapt pawlyk bs et al gene ther meiragtx corpor present chardan
figur meira construct shorter form rpgr gene due delet light blue
rpgr gene splice number differ isoform depend tissu
retina util form includ region
exon includ retin rpgr transcript inher instabl make prone
mutat like one underli mani case xlrp studi estim case
naturally-occur mutat often truncat lead loss c-termin domain rpgr
due instabl region difficult produc full-length transgen
issu earli preclin studi gene therapi xlrp
truncat protein sometim detriment due off-target domin neg effect
preclin work publish see next section studi demonstr sever truncat form
restor wild type function rod long truncat form suffici rescu cell
meira use long truncat transgen base preclin studi believ stabl
transgen carri forward clinic trial
page
meira construct restor rpgr express rod function mous model
adapt pawlyk bs et al gene ther chardan
figur treatment rpgr-/- anim restor rpgr express green express opsin yellow light respons
aav-rpgr-long call aav-rpgr restor protein express connect cilium
inner outer segment retina rpgr-/- anim
figur green repres rpgr red gener marker cilia untreat anim
green stain consist genet defect
treatment green stain restor pattern express appear similar wild type anim
treatment also restor wild type level local rhodopsin cone opsin within photoreceptor
upper panel figur rhodopsin express reduc untreat rpgr-/- mice treatment
lower panel cone opsin local order mirror wild type mice treatment
compar untreat anim
rod function measur erg restor treatment
amplitud light- dark-adapt la da signal nearli undetect rpgr-/- mice
increas aav-rpgr administr figur
page
aav-rpgr also support glutamyl newly-appreci modul rpgr function
adapt meiragtx corpor present chardan
figur treatment mini retina grown xlrp patient show aav-rpgr restor glutamyl green coloc rpgr pink
recent paper demonstr glutamyl post-transl modif protein glutam
residu import function rpgr
glutamyl nativ rpgr occur c-terminu alter lost absenc mous
model diseas rao kn et al biol open
glutamyl hypothes promot interact rpgr cargo connect cilium
discov rpgr glutamyl lost absenc protein glutamylas lead
xlrp-like diseas loss rod photoreceptor sun et al proc natl
use human mini-retina system cell xlrp patient meira collabor univers colleg
london demonstr aav-rpgr restor glutamyl cilia
untreat sampl rpgr pink stain larg absent administr aav-rpgr
particularli high dose restor detect rpgr stain wild type pattern
page
natur histori xlrp well-studi prospect trial on-going plan
adapt huang wc et al ivo chardan
figur xlrp patient reach legal blind base visual acuiti begin around year old
knowledg small natur histori nh studi conduct make diseas less understood
base publish literatur howev symptom diseas typic night blind decad
life follow loss peripher central vision decad
legal blind typic occur decad typic around year old
timelin support studi huang wc et al ivo visual
acuiti kinet field measur longitudin figur
metric vision includ visual field follow similar trajectori rpgr mutat appear drive faster
diseas progress rp gene like rho sandberg et al ivo
better understand diseas progress meira other conduct extens nh studi xlrp
meira current run studi patient age older assess retin structur
retin sensit visual field measur year
agtc on-going trial patient age older measur va visual field retin
structur photoreceptor function qol year
nightstar plan xolari nh studi run-in pivot trial nsr-rpgr
page
meira measur size ellipsoid zone surrog degener
adapt meiragtx corpor present chardan
figur chang ellipsoid zone correl diseas progress age
on-going natur histori studi compani identifi ellipsoid zone area potenti surrog
metric diseas progress
ellipsoid zone measur via optic coher tomographi oct
compris hyperreflect zone surround hyporeflect zone encompass fundu figur
transit zone area mark region activ diseas
ellipsoid zone marker degener across multipl ird
area shrink diseas progress figur
data patient collect natur histori studi year valuabl compar
patient go run-in phase i/ii
meira hypothes ellipsoid zone measur may also help patient select pivot trial
longitudin measur ellipsoid zone width area time may reveal cluster patient
similar diseas characterist progress
studi compar progress xlrp autosom rp demonstr chang size
ellipsoid zone much faster xlrp patient support pattern seen natur histori
page
meira on-going phase i/ii trial aav-rpgr adult patient
adapt meiragtx corpor present chardan
figur meira phase i/ii studi aav-rpgr similar design program incorpor pediatr cohort
phase i/ii studi run uk moorfield hospit us
earli result patient cohort suggest treatment improv metric retin sensit base
perimetri data speed/accuraci navig mobil maze low light lux
meira agtc approach pro con
note trial competitor agtc inject perform peripher avoid damag fovea
might elimin residu vision
meira damag fovea/macula retin tear could reduc remain va
agtc peripher treatment may improv function peripher cell dead longer
may distal fovea improv va
aav-rpgr receiv track design ftd fda odd fda ema
meira expect preliminari dose-escal phase i/ii data
phase i/ii patient roll extens studi long-term follow-up
page
enrol run-in nh adult per grouppediatr across groupscohort undisclos high dose cohort vg/ml follow assess month follow month follow month long-term follow year long-term follow year long-term follow year optim low doseoptim high dose plc
xlrp competit indic given multipl on-going aav-bas gt trial
adapt meiragtx corpor present chardan
figur meira face competit compani space also run phase i/ii xlrp clinic trial
nightstar fulli codon optim product express full-length rpgr
vitro corpgr express wild type construct gener lab fischer md et al mol
ther construct also subject delet insert point mutat
product prepar seen prepar wild type rpgr
nightstar construct also demonstr robust express vivo clear tight local
see data suggest otherwis favor deliber approach transgen design use
natur truncation/mut less well-understood side effect off-target effect
agtc codon optim region stabil publish efficaci dog model xlrp
work howev shorten form rpgr similar meira construct demonstr
us suggest requir codon-optim may determin clinic trial result
may ultim contribut success may absolut requir
nightstar edg time interim data safeti efficaci multipl cohort due euretina
meira preliminari data patient cohort expect complet adult dose pediatr
dose conclud interim data readout
agtc newli begun enrol patient april trial anticip complet administr
dose-escal portion trial
page
namephaseprimari complet datetri dose-escal old adult treat first pediatr rhodopsin kinas promot rhodopsin kinas sequenc human gene bp delet hing region delet affect function hing region promot hit rod cone high expressionappli genet technolog old adult treat first pediatr protein-coupl receptor kinas rhodopsin gene codon-optim region promot gene meira construct codon optim may provid addit benefit need determin empiricallynightstar rhodopsin kinas promot rhodopsin kinas codon-optim sequenc human gene trial on-going sinc march like read codon optim may provid addit benefit need determin empir meiragtx hold plc
background treatment diseas
encod enzym critic vision mutat lead multipl type ird
adapt http //photobiolog info/crouch html fda spark chardan
figur act rpe metabol all-tran retinyl ester left diagnos mani differ diseas right
encod enzym requir recycl all-tran retino acid retin pigment epitheli cell rpe
loss caus build-up all-tran retinyl ester rpe loss halt signal-
transduct cascad requir activ rhodopsin light-sens pigment rod
mutat manifest multipl diseas commonli categor leber congenit
amaurosi lca rp simplifi diagnosi patient though famili diseas refer
ird affect patient us meira estim us eu japan
mutat caus lca case retin pigmentosa rp case
symptom typic begin birth although mutat may caus later onset
first symptom difficulti see low light due rod dysfunct time cone becom impair
well lead loss central vision blind adulthood
fda approv first therapeut ird luxturna aav-bas gene therapi
luxturna product transgen control cmv enhanc ca
promot approv use patient year age bi-allel mutat
page
meira gener product improv ucl precursor
adapt meiragtx chardan
figur number chang made construct test clinic trial order deriv meira current asset
result phase i/ii studi prior construct publish nejm bainbridg jwb
et al new eng demonstr limit transient efficaci
patient treat low dose vg see signific improv retin sensit
patient treat high dose vg saw meaning improv wane month
chang va erg seen timepoint
vector administ fovea improv function cell site
immun respons dose-limit toxic limit util construct
subsequ year construct improv make clinic tractabl
chang outlin figur includ capsid promot transgen
sequenc codon optim mrna stabil ad
preclin result construct publish georgiadi et al gene ther
compar previou product optim version increas transduct effici protein express
erg respons mice
anim model mous rabbit dose-limit inflammatori respons detect clinic dose
tox studi mice rabbit minipig meira support observ
page
meira also conduct natur histori studi understand diseas progress
adapt jacobson sg et al proc natl chardan
figur foveal onl thick visual acuiti declin time blind occur around year age
studi jacobson sg et al proc natl provid evid va loss
occur year age
one first manifest night blind usual present birth
anoth earli life present reduct outer nuclear layer onl thick compar healthi control
although magnitud thin vari among patient
onl thick particularli close fovea also seem decreas time chang seen
control group rang age
va chang mirror loss foveal thick time pronounc loss va occur
decad life
meira on-going natur histori studi provid addit clariti cours diseas
trial enrol patient year observ number function structur readout
structur color fundu imag oct adapt optic
compani anticip outcom studi inform design pivot trial
page
luxturna approv improv mlmt without va chang
adapt arvo poster present chardan
figur luxturna-tr patient improv mlmt score va
luxturna aav-bas gt approv us decemb base novel endpoint one
historically-approv ophthalmolog endpoint
past ophthalmolog product approv base improv va often etdr letter
contrast sensit cs visual field color vision
spark part luxturna clinic develop process establish multi-lumin mobil test mlmt
measur function vision incorpor aspect va cs readili measur standard
metric maze scenario design mimic real world
although compani demonstr clear improv mlmt score treatment luxturna
chang correspond improv va
meira aim demonstr improv va along chang speed accuraci navig maze
function readout includ visual function one key measur plan meira phase i/ii studi
perimetri determin chang retin sensit pre- post-treat treat fellow eye
visual field model analysi vfma erg navig speed accuraci maze
structur readout anoth import compon program particularli measur cone map
time retin thick
page
meira phase i/ii trial ol studi use fellow eye control
adapt meiragtx chardan
figur meira phase i/ii trial test multipl cohort multipl site administr
meira conduct phase i/ii trial current on-going moorfield site us
may patient treat patient consent long-term follow
compani test foveal peripher administr
patient cohort treat foveal reach month post-treat report advers event
foveal includ foveal thin loss cone patient demonstr improv central visual
function compar either baselin fellow eye sensit improv month
patient improv speed accuraci navig maze timepoint
patient cohort treat peripher inflammatori respons even steroid taper
inflamm resolv addit steroid administr outer retina pursu
patient exhibit improv maze result chang retin sensit
pediatr patient dose lowest dose fovea enrol complet
rpdd fda odd fda ema
preliminari result treat patient anticip
design trial open-label ol studi structur achromatopsia studi
note spark use cross-ov design phase order includ placebo control
page
enrol run-in nh adult per grouppediatr vg/ml cohort peripher administr cohort vg/ml foveal administr follow assess month follow month follow month long-term follow year long-term follow year long-term follow year vg/ml foveal administr plc
meira construct luxturna target patient
adapt clinicaltri gov corpor report chardan
figur meira hope improv upon result obtain luxturna
notabl differ luxturna meira product
vector differ vs promot ca vs
see like tropic rpe cell may improv meira result transduct effici
good visibl rel strength differ promot novel promot
develop meira collabor note choic promot critic
meira codon-optim transgen compani work codon-optim product see figur
unknown us time influenc outcom patient
product were/ar test would indic potenti use overlap popul
therefor conserv yet model risk-adjust forecast
luxturna approv use patient confirm biallel mutation-associ retin dystrophi
year age older
broad luxturna label could mean mani patient treat time meira product approv
page
namephaseprimari complet datetri dose-escal old adult treat first pediatr optim human plu intron optim kozak sequenc product express gener construct accord compani import codon optim remain demonstr human meira hope demonstr improv va metric visual functionspark therapeuticsluxturnamarket random control beta actin promot plu cmv human gene luxturna first aav-bas gt approv fda evid luxturna treatment improv visual acuiti visual field improv function vision measur multi-lumin mobil test meiragtx hold plc
background preclin program develop
aav-aipl releas compassion use uk
adapt den holland ai et al prog ret sun et al ther chardan
figur meira avail compassion use base anim data
meira develop treatment leber congenit amaurosi rarer lca subtyp
mutat critic chaperon protein rod photoreceptor figur account lca case
overal incid lca birth make mutat rare
diseas onset earli life visual acuiti deterior rapidli due death rod
therapi approv blind caus mutat
preclin work sun el al gene ther indic effect restor rod surviv
morpholog mous model diseas
use vector express control rhodopsin kinas rk promot
research abl restor rod function measur higher erg respons figur
rod surviv increas correct histopatholog chang includ loss outer segment retina
result promis human use diseas epidemiolog natur histori allow robust
clinic test thu meira elect distribut via special licens compassion use uk
test adult rod alreadi die would provid inform safeti efficaci preclud
page
preclin studi underway develop therapi dri wet
adapt forrest jv et al front immunol chardan
figur form age-rel macular degener lead caus blind adult us
age-rel macular degener common caus loss vision patient us
character decreas central vision time
million patient affect us million patient world-wide
dri meira test gene therapi convert peripher rod cone
patient suffer dri damag caus build-up debri lead
inflamm cell death retina current treatment dri
loss central vision advanc light sens peripher rod
improv residu sight meira develop aav therapi convert rod sensit cone
wet meira develop aav-bas
wet caus neovascular choroid spread retina
vessel leak fluid caus edema subsequ drive loss central vision
anti-vegf inject effect therapi adher weak
aav-bas deliveri anti-vegf receptor would prevent signal excess vegf retina
note competit gt compani develop aav-bas anti-vegf therapi like buy
chardan top pick phase clinic trial progress cohort due
begin neutral submit ind intravitr gt
compani intend file ind
page
meira develop aav-bas therapi treat multipl form al
adapt guerrero en et al prog neurobiol wikipedia chardan
figur implic pathogenesi al base role nonsense-medi decay nmd pathway
accumul fu dna/rna bind protein involv shuttl compon
nucleu cytoplasm neuron link amyotroph later sclerosi al pathogenesi
link proport al case suggest aberr accumul protein
dysregul rna transport regulatori process could underli spontan al
upregul compon nonsense-medi decay nmd pathway may help reduc al patholog
act part complex degrad mutant rna transcript nmd
activ nmd may help resolv al patholog counteract accumul rna substrat
meira develop potenti therapi al caus varieti mutat exclud
administr could help resolv cellular stress caus accumul mutant rna
compani intend file ind
page
meira also develop aav-bas therapi treat alzheim diseas
adapt small sa et al neurosci small sa et al trend neurosci chardan
figur retrom involv retrograd transport critic pathway neuron
endosom traffick recent appreci potenti underli caus alzheim diseas
retrom multi-protein complex regul retrograd transport endosom back golgi apparatu
transport mechan particularli import neuron regul synapt receptor densiti
composit well neurotransmitt
retrom dysfunct hypothes possibl caus alzheim due gener
neurotox protein fragment reduc number cell surfac receptor harm protein aggreg
accumul due lack transport proteas throughout cell
meira preclin test identifi retrom compon could effect target aav-bas gt
alzheim diseas possibl parkinson diseas
aav-bas deliveri could provid durabl result although earli intervent may necessari
given size retrom complex select effect target import
part program meira develop novel minimally-invas biomark endosom dysfunct
page
novel mammalian riboswitch may allow meira develop tunabl
adapt di palma et al bmc bioinfo chardan
figur riboswitch control small molecul rb sequest induc absent expos present
meira develop mammalian riboswitch histor difficult
riboswitch may allow transgen turn
riboswitch secondari rna structur includ site bind small molecul highli specif
small molecul induc absent ribosom bind site rb sequest therefor
translat occur
induc ad system dna chang conform expos rb allow gene
embed switch gt construct would allow target express
regul transgen express deliveri gt new horizon potenti innov space
addit promot regul transgen express cell type-depend manner
riboswitch would provid abil control express temporally-specif manner
meira program still earli develop could provid sourc asset long term
page
background meira remark in-hous manufactur capabl
adapt genet engin biotechnolog news chardan
figur aav manufactur involv process meira work streamlin intern procedur make scalabl
meira construct squar foot manufactur facil london
compani announc facil mhra-certifi june
facil contain cell cultur suit viral vector product suit
allow manufactur multipl product simultan
compani anticip capac suffici produc vector clinic preclin studi well
potenti futur commerci
facil also includ space key analyt qualiti control test critic compon
manufactur process note ema stringent requir fda product
investig product meira recent certif attest compani profici
manufactur process base proprietari cell line grown adher suspens
cultur thu provid option scale-up futur product necessari
meira recruit experienc profession overse manufactur
stuart naylor meira chief develop offic previous chief scientif offic oxford biomedica
jame christi meira svp manufactur suppli chain work head manufactur innov
project director medicin manufactur industri partnership employ
associ british pharmaceut industri also previous employ oxford biomedica
ian delmag meira head qualiti senior complianc profession novarti nr
page
figur meiragtxincom statement million except ep
page
million except gener oper incom incom incom incom incom incom basic dilut ep ep cash shareholdersdividend size incom gener oper incom incom incom incom incom incom plc
sale key product
figur meiragtxproduct revenu revenu million
page
therapeut pi/ii gt pc gt pi/ii gt pi/ii gt pi/ii gt inj pc gt inj pc ab drop pc unknown product sale yoy plc
figur meiragtxdiscount cash flow dcf analysi million
page
million except per share net depreci capit increas work defer non-cash free cash first year cash unlev free cash period discount period discount year mid-year factor free cash valu unlev free cash pv forecast unlev free cash valu perpetu growth valu termin termin ebitda xenterpris valu per dilut assumptionswacc calculationsbal sheetdcf valu alloc product cash fiscal year end fiscal year end xero project discount pipelin al project discount per cash per dilut share price valu per perpetu growth market cap august share exercis share restrict ordinari model dilut million plc
